NYMC Faculty Publications
First Page
26
Last Page
26
Document Type
Article
Publication Date
7-26-2016
Department
Medicine
Keywords
cell therapy, acute lymphoblastic leukemia (ALL), blinatumomab, hyperCVAD regimen
Disciplines
Oncology
Abstract
Background
The current standard of care for relapsed and refractory acute lymphoblastic leukemia (ALL) is combination chemotherapy.
Case presentation
We report a case of highly refractory ALL who was treated with blinatumomab. The ALL in this patient relapsed within a month after completion of hyperCVAD regimen and was refractory to high dose mitoxantrone/cytarabine and CLAG regimens.
Conclusion This highly refractory pre-B Ph− ALL was induced to complete remission after one course of single agent blinatumomab.
Recommended Citation
Li, Z., & Liu, D. (2016). Cell therapy must be regulated as medicine. Experimental Hematology & Oncology, 5, 26. doi:10.1186/s40164-016-0055-0
Publisher's Statement
Originally published in Experimental Hematology & Oncology. Licensed under CC-BY 4.0. https://doi.org/10.1186/s40164-016-0055-0
